Mirati Therapeutics provides update on the phase III SAPPHIRE study evaluating sitravatinib in combination with Opdivo in NSCLC.
Mirati Therapeutics, Inc. announced that the SAPPHIRE study did not meet its primary endpoint of overall survival at the final analysis
SAPPHIRE is a Phase III study evaluating sitravatinib in combination with nivolumab (Opdivo) versus docetaxel in patients with second or third line advanced non-squamous non-small cell lung cancer (NSQ-NSCLC) who progressed on prior therapy with chemotherapy and immune checkpoint inhibitor therapy. The company plans to disclose the study data at a future date.
Principal Investigators will be given the option to continue therapy for patients who are experiencing clinical benefit and would like to remain on treatment.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.